Samsung chief admits to sedative use

SEOUL: The de facto leader of South Korea’s sprawling Samsung Group Jay Y. Lee pleaded guilty in court yesterday to a charge of unlawful use of a controlled substance, as legal woes continue to haunt the executive even after his release on parole in August following a bribery conviction.

Lee’s release had raised market watchers’ expectations of a flurry of major decisions at crown jewel Samsung Electronics Co Ltd and its affiliates, including the location of a $17 billion chip factory being planned in the United States.

But Lee’s legal troubles continued yesterday at the Seoul Central District Court where, in a short first hearing on the matter, Lee said he received propofol — a sedative used in anaesthesia — 41 times from 2015 through 2020.

Prosecutors said that the use was under the guise of skin treatment or unrelated to a legitimate treatment.

“This matter originated as for treatment, but I am deeply regretful. I will ... make sure that this does not happen again,” Lee told the small court of about 15 people.

He said he had not used the drug since his August release.

Lee originally sought treatment due to psychological pressure since his father’s 2014 hospitalisation, which intensified with the subsequent graft scandal and trial that led to his January conviction, his lawyer said.

Prosecutors are seeking a fine of 70 million won ($58,327) and an additional fee of 17 million won. The ruling will be on Oct 26.

Under South Korean law, the recipient of a controlled substance deemed to have been administered illegally is liable for prosecution, as well as those who administered the drug.

Staff at a clinic where Lee received the sedative, who are being tried separately, have denied wrongdoing.

As propofol is less likely to be misused than many other controlled substances, many similar cases of unlawful use have resulted in fines rather than jail terms.